Search research articles
Contact Us
Filters
Showing results (31-40 of 77) with videos related to
Page
of 8
Sort By:
Blood Cancer Journal
|
August 21, 2021
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Franck Morschhauser, Nilanjan Ghosh, Izidore S Lossos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma
Sarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Leukemia & Lymphoma
|
November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Morton Coleman, David Belada, René-Olivier Casasnovas, et al.
Oncotarget
|
April 21, 2017
Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets
Eddy S Yang, Christopher D Willey, Amitkumar Mehta, et al.
Blood Advances
|
August 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Amitkumar Mehta, Leslie Popplewell, Graham P Collins, et al.
Haematologica
|
September 28, 2023
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Christopher R Flowers, Matthew J Matasar, Alex F Herrera, et al.
The Lancet. Oncology
|
May 19, 2019
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
Hervé Tilly, Franck Morschhauser, Nancy L Bartlett, et al.
Plos One
|
September 26, 2015
High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes
Joshua C Anderson, Christopher D Willey, Amitkumar Mehta, et al.
European Urology Focus
|
July 30, 2017
Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets
Andrea Necchi, Bernhard J Eigl, Eddy Shih-Hsin Yang, et al.
Translational Behavioral Medicine
|
February 2, 2018
Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education
Gabrielle B Rocque, Courtney P Williams, Karina I Halilova, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 77) with videos related to
Sort By:
Page
of 8
Blood Cancer Journal
|
August 21, 2021
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Franck Morschhauser, Nilanjan Ghosh, Izidore S Lossos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma
Sarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Leukemia & Lymphoma
|
November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Morton Coleman, David Belada, René-Olivier Casasnovas, et al.
Oncotarget
|
April 21, 2017
Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets
Eddy S Yang, Christopher D Willey, Amitkumar Mehta, et al.
Blood Advances
|
August 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Amitkumar Mehta, Leslie Popplewell, Graham P Collins, et al.
Haematologica
|
September 28, 2023
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Christopher R Flowers, Matthew J Matasar, Alex F Herrera, et al.
The Lancet. Oncology
|
May 19, 2019
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
Hervé Tilly, Franck Morschhauser, Nancy L Bartlett, et al.
Plos One
|
September 26, 2015
High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes
Joshua C Anderson, Christopher D Willey, Amitkumar Mehta, et al.
European Urology Focus
|
July 30, 2017
Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets
Andrea Necchi, Bernhard J Eigl, Eddy Shih-Hsin Yang, et al.
Translational Behavioral Medicine
|
February 2, 2018
Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education
Gabrielle B Rocque, Courtney P Williams, Karina I Halilova, et al.
Page
of 8